Skip to main content
. Author manuscript; available in PMC: 2018 Dec 12.
Published in final edited form as: Sci Transl Med. 2015 Sep 23;7(306):306ra151. doi: 10.1126/scitranslmed.aab1720

Figure 4. JCV-neutralizing titers following vaccination of PML patient 5228.

Figure 4.

Patient 5228 was administered JCV VLPs subcutaneously at three time points (downward purple triangles). Recombinant IL-7 was also administered for two cycles each consisting of a subcutaneous weekly dose of 10 µg/kg (upward green triangles). The patient’s neutralizing titer against her cognate PML-mutant JCV (red squares) or inferred wt JCV (blue circles) was monitored over time. JCV load in the patient’s plasma (gray dots) was also monitored over time. See Supplementary Materials for additional patient details.